Abstract
Complications of embolization and chemoembolization remain a problem even with the development of low-profile catheter material and the introduction of new embolization agents. In recent years many new embolization materials have become available for clinical use, so the possibilities and limitations of these new materials must be understood to allow safe and effective embolization. Although up to now some scientific work has been published reporting the basic risk of embolization procedures, the underlying pathomechanism remains the object of speculation. Besides complications like drug toxicity, allergic reactions, and bleeding of the puncture site, the characteristics of embolization materials must be known to understand the potential complications of nontarget embolization and reflux of embolization material. This article gives an overview of established and new embolization materials, their potential risks, and the underlying pathophysiology.
Similar content being viewed by others
References
Liapi E, Geschwind JF (2007) Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 25:978–986
Lohle PN, Boekkooi FP, Smeets AJ et al (2006) Limited uterine artery embolization for leiomyomas with tris-acryl gelatin microspheres: 1-year follow-up. J Vasc Interv Radiol 17:283–287
Sakamoto I, Aso N, Nagaoki K et al (1998) Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 18:605–619
Lopez-Benitez R, Radeleff BA, Barragan-Campos HM et al (2007) Acute pancreatitis after embolization of liver tumors: frequency and associated risk factors. Pancreatology 7:53–62
Malagari K, Chatzimichael K, Alexopoulou E et al (2008) Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Interv Radiol 31:269–280
Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC (2001) Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 12:321–326
Sharara AI, Rockey DC (2001) Gastroesophageal variceal hemorrhage. N Engl J Med 345:669–681
O’Rourke MF, Nichols WW (2007) Timing and amplitude of wave reflection. Hypertension 49:E3, author reply E4
Mitchell GF (2006) Triangulating the peaks of arterial pressure. Hypertension 48:543–545
O’Rourke MF, Nichols WW, Murgo JP (2007) Noninvasive input impedance of the human systemic circulation. Hypertension 50:e16, author reply e17
Stampfl S, Stampfl U, Rehnitz C et al (2007) Experimental evaluation of early and long-term effects of microparticle embolization in two different mini-pig models. Part I: Kidney. Cardiovasc Interv Radiol 30:257–267
Derdeyn CP, Graves VB, Salamat MS, Rappe A (1997) Collagen-coated acrylic microspheres for embolotherapy: in vivo and in vitro characteristics. Am J Neuroradiol 18:647–653
Siskin GP, Dowling K, Virmani R, Jones R, Todd D (2003) Pathologic evaluation of a spherical polyvinyl alcohol embolic agent in a porcine renal model. J Vasc Interv Radiol 14:89–98
Siskin GP, Englander M, Stainken BF, Ahn J, Dowling K, Dolen EG (2000) Embolic agents used for uterine fibroid embolization. AJR 175:767–773
Stampfl S, Stampfl U, Rehnitz C et al (2007) Experimental evaluation of early and long-term effects of microparticle embolization in two different mini-pig models. Part II: liver. Cardiovasc Interv Radiol 30:462–468
Huo TI, Lui WY, Wu JC et al (2004) Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence. World J Surg 28:258–262
Kothary N, Weintraub JL, Susman J, Rundback JH (2007) Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 18:1517–1526
Wu SC, Chen RJ, Yang AD, Tung CC, Lee KH (2008) Complications associated with embolization in the treatment of blunt splenic injury. World J Surg 32(3):476–482
Takayasu K, Moriyama N, Muramatsu Y et al (1984) Splenic infarction, a complication of transcatheter hepatic arterial embolization for liver malignancies. Radiology 151:371–375
Khankan AA, Osuga K, Hori S, Morii E, Murakami T, Nakamura H (2004) Embolic effects of superabsorbent polymer microspheres in rabbit renal model: comparison with tris-acryl gelatin microspheres and polyvinyl alcohol. Radiat Med 22:384–390
Stampfl S, Bellemann N, Stampfl U et al (2008) Inflammation and recanalization of four different spherical embolization agents in the porcine kidney model. J Vasc Interv Radiol 19:577–586
Lewis AL, Adams C, Busby W et al (2006) Comparative in vitro evaluation of microspherical embolisation agents. J Mater Sci: Mater Med 17:1193–1204
Laurent A, Wassef M, Saint Maurice JP et al (2006) Arterial distribution of calibrated tris-acryl gelatin and polyvinyl alcohol microspheres in a sheep kidney model. Invest Radiol 41:8–14
Laurent A, Wassef M, Chapot R, Houdart E, Merland JJ (2004) Location of vessel occlusion of calibrated tris-acryl gelatin microspheres for tumor and arteriovenous malformation embolization. J Vasc Interv Radiol 15:491–496
Yang X (2007) Nano- and microparticle-based imaging of cardiovascular interventions: overview. Radiology 243:340–347
Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342
Nakamura H, Hashimoto T, Oi H, Sawada S, Furui S (1991) Prevention of gastric complications in hepatic arterial chemoembolization. Balloon catheter occlusion technique. Acta Radiol 32:81–82
Dai H, Ding H, Liu F et al (2007) Complications of chemoembolization for hepatic neoplasms. Saudi Med J 28:1208–1212
Prollius A, du Plessis A, Nel M (2005) Uterine artery embolization in HIV positive patients. Int J Gynaecol Obstet 88:67–68
Chung JW, Park JH, Han JK et al (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33–40
Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261
Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917
Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481
Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739
Roullet MH, Denys A, Sauvanet A, Farges O, Vilgrain V, Belghiti J (2002) Acute clinical pancreatitis following selective transcatheter arterial chemoembolization of hepatocellular carcinoma. Ann Chir 127:779–782
Xia J, Ren Z, Ye S et al (2006) Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol 59:407–412
Kauffmann GW, Richter GM, Rohrbach R, Wenz W (1989) Prolonged survival following palliative renal tumor embolization by capillary occlusion. Cardiovasc Interv Radiol 12:22–28
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
López-Benítez, R., Richter, G.M., Kauczor, HU. et al. Analysis of Nontarget Embolization Mechanisms During Embolization and Chemoembolization Procedures. Cardiovasc Intervent Radiol 32, 615–622 (2009). https://doi.org/10.1007/s00270-009-9568-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-009-9568-9